ERBB2 and prostate cancer: Many clinical biomarkers and therapeutic targets in cancer are glycoproteins [93–95], such as CA125 in ovarian cancer, HER2/neu in breast cancer, and prostate-specific antigen (PSA) in prostate cancer.